Bringing expertise in a wide range of life science technologies
Poh K. Teng, PhD, focuses her practice on US and International patent preparation, prosecution, and client counseling. Poh has 14 years of scientific research expertise in basic and applied biological research, including protein structure and function, strain and pathway engineering, amyloid diseases, cancer biology, and infectious disease. Poh’s broad technical expertise serves as the foundation for her IP practice in a variety of life science technologies.
“Identification of a minimal peptide tag for in vivo and in vitro loading of encapsulin,” Biochemistry, May 25, 2016 (coauthor).
“Programmed ribosomal frameshifting mediates expression of the α‐carboxysome,” J Mol Biol, January 16, 2016 (coauthor).
“Toxic fibrillar oligomers of amyloid‐β have cross‐β structure,” Proc Natl Acad Sci USA,
May 15, 2012 (coauthor).
“Atomic view of a toxic amyloid small oligomer,” Science, March 9, 2012 (coauthor).
“Modularity of a carbon‐fixing protein organelle,” Proc Natl Acad Sci USA, January 10, 2012
“Ribonuclease A suggests how proteins self‐chaperone against amyloid fiber formation,”
Protein Sci, November 16, 2011 (coauthor).
“Identifying the amylome, proteins capable of forming amyloid‐like fibrils,” Proc Natl Acad Sci
USA, February 23, 2010 (coauthor).
“Short protein segments can drive a non‐fibrillizing protein into the amyloid state,” Protein Eng
Des Sel, July 14, 2009 (coauthor).
“A novel CYR61‐triggered 'CYR61‐avb3 integrin loop' regulates breast cancer cell survival and
chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway,” Oncogene,
December 13, 2004 (coauthor).
“Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for
breast cancer chemoprevention through its ability to suppress Her‐2/neu (erbB‐2) oncogeneinduced
malignant transformation,” Mol Carcinog, September 23, 2004 (coauthor).